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It is of great therapeutic importance to understand why tumors relapse after the failure of therapies
targeting oncogenes to which cancer cells are addicted. In this issue, Kapoor et al. and Shao et al.
identify the transcriptional coactivator YAP1 as a central driver of compensation for the loss of
K-Ras signaling in K-Ras-dependent cancers.Targeted therapies of oncogene-addicted
tumors have led to significant clinical
responses in various malignancies,
including Erb2 overexpressing breast
cancer, chronic myelogeneous leukemia
harboring the BCR-ABL translocation,
non-small cell lung cancer with a subset
of EGFR mutations, or BRAFmutant mel-
anoma (Torti and Trusolino, 2011). Unfor-
tunately, in almost all cases, resistance
development and tumor relapse occur.
Somatic mutations in KRAS belong
to the most common activating lesions
found in human cancer, including
pancreas, lung, and colon cancer (Kar-
noub and Weinberg, 2008). Thus, K-Ras
inhibition bears great clinical impact,
yet identification of potential resistance
mechanisms is of enormous therapeutic
relevance. In this issue ofCell, two studies
provide compelling evidence that Yes-
associated protein 1 (YAP1) can substi-
tute for loss of KRAS in human and
murine cancers.
Pancreatic ductal adenocarcinoma
(PDAC) represents one of the best exam-
ples of a tumor with a very high depen-
dence on oncogenic KRAS, and the
DePinho group had recently demon-
strated that sustained K-Ras activation
is essential for maintenance of PDAC
(Ying et al., 2012). In a very elegant report,
the same group now employs a genetic
mouse model to examine the long-term
effects upon shutdown of oncogenic
K-Ras in established pancreatic cancer
(Kapoor et al., 2014). As expected, all tu-
mors initially regress within 3 weeks after
K-rasG12D extinction; however, more than
two-thirds of tumors begin to relapse af-
ter about 2 months. These are confirmedto be bona fide tumor relapses yet display
a more aggressive phenotype with a
higher number of distant metastases.
Although MEK/ERK signaling is activated
in about half of the relapsed tumors due
to re-expression of the Kras transgene,
the other half of tumors is characterized
by amplification of chromosome 9qA1
encompassing genes coding for the tran-
scriptional coactivator Yap1 and the
antiapoptotic genes Birc2 and Birc3.
Of these, only knockdown of Yap1
affects pancreatic cancer cell growth,
and enforced Yap1 expression enables
pancreatic tumor maintenance even in
the absence of oncogenic K-Ras in vivo.
Although Yap1 is known to interact with
Smad1, p73, Runx2, and TEAD transcrip-
tion factors (Zhao et al., 2011), the au-
thors demonstrate in the pancreatic
cancer model that Yap1 complexes spe-
cifically with Tead2. This complex then
cooperates with E2F transcription factors
to activate genes controlling cell cycle
and DNA replication. Accordingly, domi-
nant-negative E2F1 suppresses prolifera-
tion of YAP1-expressing cancer cells,
underscoring the importance of E2F1 ac-
tivity for YAP1/Tead2-mediated bypass
of tumor regression in the absence
of oncogenic K-Ras. Importantly, the
authors highlight the clinical importance
of their findings. Most YAP1-expressing
relapse tumors express gene signatures
comparable to the human quasimesen-
chymal subtype of PDAC, which in
contrast to the other two PDAC subtypes
(classical and exocrine-like), is known to
express lower levels of KRAS and to be
less KRAS dependent. Indeed, YAP1
proves to be essential for growth of tumorCcell lines derived from quasimesenchymal
tumors.
Based on the results of a genome-
scale screen Hahn, Jacks, and col-
leagues describe that YAP1 can specif-
ically compensate the shRNA-mediated
loss of K-Ras function in KRAS mutant
colon and pancreatic cancer cell lines
(Shao et al., 2014). In contrast to the
study by DePinho here, YAP1 functions
independently of TEAD. Instead, YAP1
controls the AP-1 family transcription
factor FOS and epithelial-mesenchymal
transition (EMT). YAP1 specifically inter-
acts with FOS, but not with other AP-1
family members such as Jun to coordi-
nately regulate downstream targets
involved in EMT, including vimentin and
slug. Using an oncogenic K-Ras-depen-
dent lung cancer model, the authors
confirm rapid tumor regression upon
loss of K-Ras signaling as well as
K-Ras-independent tumor relapse shortly
after. Cell lines obtained from these
K-Ras-silenced tumors show a YAP1
signature as well as altered expression
of various EMT markers. When K-Ras
and YAP1 are both silenced in the lung
tumor model in vivo, tumor relapse is de-
layed; however, in these tumors, YAP1 is
not silenced anymore.
The Hippo pathway controls YAP1
activity via activation of the kinases
MST1 and MST2 as well as LATS1 and
LATS2. This pathway is involved in em-
bryonic development, tissue homeo-
stasis, and tumorigenesis (Zhao et al.,
2011). YAP itself acts as an oncogene
both in vitro and in vivo and is frequently
amplified in a wide range of cancers,
including breast and liver, controlling cellell 158, July 3, 2014 ª2014 Elsevier Inc. 11
Figure 1. YAP1 Compensates for Loss of Oncogenic K-Ras to
Sustain Tumor Maintenance
Depending on the cellular context, YAP1 activates distinct transcriptional
programs to substitute for loss of oncogenic K-RAS. In pancreatic ductal
adenocarcinoma (PDAC), YAP1 complexes with TEAD2 to drive a E2F1-
dependent cell cycle and DNA replication program and shifts tumors to amore
aggressive quasimesenchymal phenotype. MAPK and PI3 kinases are not
activated. In colon and lung cancer, YAP1 interacts with FOS to induce an
epithelial-mesenchymal transition (EMT) program in the absence of K-Ras
signaling. MAPK and PI3K are hyperactive. Certain members of the E2F and
ATF transcription factor families can be found activated in both instances;
some others are active only in PDAC (CREB1) or colon cancer (c-MYC, HIF).proliferation, EMT, invasion,
and metastasis. The two
studies published here add a
new central function for
YAP1: they place YAP1 as
an essential bypass in K-
Ras-dependent tumors once
K-Ras signaling is silenced
(Figure 1). Using independent
in vivo and ex vivo ap-
proaches in different cancer
entities, both studies identify
YAP1 as the primary substi-
tute for K-Ras. Intriguingly,
the responsible downstream
effector mechanisms ulti-
mately leading to tumor
relapse differ in distinct tumor
entities despite the fact that
YAP1 is involved in both
cases. Presumably this is
due to the context-dependent
versatility of YAP1 to interact
with various transcription fac-
tors. Considering the high
frequency of KRAS mutant
cancers as well as the factthat K-Ras is slowly losing its ‘‘undrug-
gable’’ status (Ostrem et al., 2013), these
two studies mark a great step forward in
the efforts to identify potential resistance
mechanisms. Moreover, recently devel-
oped YAP1 inhibitors targeting YAP-
TEAD complexes may become of in-
creasing value (Stanger, 2012). So far,
this may be limited to treatment of liver,
pancreatic, and gastric cancer when
YAP-TEAD complexes are involved.
Importantly, however, such compounds
may function even in the presence of
oncogenic K-Ras, as loss of YAP1 pro-
tects from PDAC development also
when K-Ras signaling is intact (Zhang
et al., 2014). In PDAC and K-Ras-silenced12 Cell 158, July 3, 2014 ª2014 Elsevier Inc.colon cancer cells, YAP1 seems to be
activated independently of the Hippo
pathway. This raises the question of
what the responsible K-Ras-controlled
and -independent pathways are that
trigger YAP1 activation under various con-
ditions. In K-Ras-silenced PDAC, chro-
mosomal amplifications cause increased
YAP1 copy numbers (Kapoor et al.,
2014). However, in lung and colorectal
cancer, this does not seem to be the
case. It is possible that there are common
context-specific YAP activators that
may also explain the interaction with
distinct transcription factors, which may
ultimately allow more feasible therapeutic
targeting of this central coactivator. Thesenew studies undoubtedly pro-
vide a compelling rationale to
target YAP1.
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